# KRT-232

Source: https://onco.cc/drugs/krt-232/  
OnCo record `krt-232` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53.

## Summary

KRT-232 is a small-molecule drug developed by Kartos Therapeutics. Its targets are MDM2 and TP53 (the sponsor names MDM2-p53 interaction). The sponsor states: A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin. ClinicalTrials.gov describes the intervention as: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in myeloproliferative neoplasms, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT04502394, plans to enrol 84 participants with primary completion was scheduled for 2022-10 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin.

## Sources

- ClinicalTrials.gov: trials of KRT-232: https://clinicaltrials.gov/search?intr=KRT-232
- Sponsor page: https://www.kartosthera.com

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- targets: [MDM2](https://onco.cc/targets/mdm2/), [TP53](https://onco.cc/targets/tp53/)
- companies: [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/)
- trials: [KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera](https://onco.cc/trials/nct03669965/), [Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL](https://onco.cc/trials/nct04502394/), [Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer](https://onco.cc/trials/nct05797831/)

---
JSON: https://onco.cc/api/v1/entities/krt-232.json